Supplemental Materials

Contents

Supplemental Tables

- Table S1. Number of first and second dose by vaccine type until 14 February 2022.
- Table S2. Calculation of the average SARS-CoV-2 vaccination interval between the first and second dose.
- Table S3. Characteristics of all-cause and myocarditis death in reference population.
- Table S4. Rate ratio for all-cause death by age by dose of vaccination.
- Table S5. Mortality odds ratio for myocarditis death by age.
- Table S6. Causal inference of increased risk of myocarditis mortality and SARS-CoV-2 vaccine useby applying modified US Surgeon General's criteria of causality referencing Hill's viewpoints.

Supplemental Figures

Figure S1. Examples of description in the Summary List of Deaths Following SARS-CoV-2 vaccination used by Japan's Ministry of Health, Labour and Welfare's Expert Committee on vaccination and adverse reactions.

Figure S2a. Method for counting deaths in the reference population.

Figure S2b. Method for counting deaths in the vaccinated population.

Table S1. Number of first and second dose by vaccine type until 14 February 2022.

	Number of first	Number of second	Total
	dose	dose	Total
BNT162b2 (Pfizer-BioNTech)	85 326 300	84 023 380	169 349 680
mRNA-1273 (Moderna)	16 306 586	16 090 036	32 396 622
ChAdOx1 nCoV-19 (Astra Zeneca)	58 549	58 300	116 849
Total			201 863 151

Table S2. Calculation of the average SARS-CoV-2 vaccination interval between

the first and second dose.				
	Interval between		Waightad avarage	
	first and second	Number of second dose *b	internal (dava)	
	dose *a		interval (days)	
BNT162b2 (Pfizer-BioNTech)	21	84 023 380		
mRNA-1273 (Moderna)	28	16 090 036		
ChAdOx1 nCoV-19 (Astra Zeneca)	40	58 300		
Total		100 171 716	22.14	

*a: Taken from the vaccine package insert.

*b: Information at 14 February 2022.

Table S3. Characteristics of all-cause and myocarditis death in reference population.

		All-cause	Myocarditis			
		N (%)			N (%)	
Year	2017	2018	2019	2017	2018	2019
Total	1 337 761 (100)	1 359 714 (100)	1 378 395 (100)	152 (100)	166 (100)	145 (100)
Age						
(years)						
10-19	1 598 (0.1)	1 606 (0.1)	1 603 (0.1)	7 (4.6)	6 (3.6)	3 (2.1)
20-29	4 302 (0.3)	4 222 (0.3)	4 097 (0.3)	5 (3.3)	13 (7.8)	2 (1.4)
30-39	8 004 (0.6)	7 724 (0.6)	7 455 (0.6)	7 (4.6)	12 (7.2)	6 (4.1)
40-49	22 838 (1.7)	22 339 (1.6)	21 837 (1.7)	10 (6.6)	15 (9.0)	23 (15.9)
50-59	46 591 (3.5)	46 873 (3.4)	46 935 (3.5)	19 (12.5)	20 (12.0)	15 (10.3)
60-69	137 354 (10.3)	129 720 (9.5)	121 635 (10.3)	26 (17.1)	39 (23.5)	27 (18.6)
70-79	264 972 (19.8)	272 804 (20.1)	281 734 (19.8)	37 (24.3)	30 (18.1)	34 (23.4)
80-89	496 298 (37.1)	501 838 (36.9)	501 343 (37.1)	34 (22.4)	24 (14.5)	26 (17.9)
≥ 90	355 335 (26.6)	372 189 (27.4)	391 272 (26.6)	7 (4.6)	7 (4.2)	9 (17.9)
Unknown	469 (0.0)	399 (0.0)	484 (0.0)	0 (0)	0 (0)	0 (0)
Sex						
Male	689 264 (51.5)	697 666 (51.3)	705 983 (51.5)	99 (65.1)	91 (54.8)	83 (57.2)
Female	648 497 (48.5)	662 048 (48.7)	672 412 (48.5)	53 (34.9)	75 (45.2)	62 (42.8)
Unknown	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

	First dose							Second dose			
Age (years)	Ob	Ex	Rate ratio	LL	UL	Ob	Ex	Rate ratio	LL	UL	
12-19	4	60	0.07	0.02	0.17	2	73	0.03	0.00	0.10	
20-29	12	210	0.06	0.03	0.10	19	260	0.07	0.04	0.11	
30-39	8	371	0.02	0.01	0.04	24	462	0.05	0.03	0.07	
40-49	19	1 1 1 9	0.02	0.01	0.03	33	1 399	0.02	0.02	0.03	
50-59	42	2 729	0.02	0.01	0.02	48	3 423	0.01	0.01	0.02	
60-69	71	6 471	0.01	0.01	0.01	50	8 133	0.01	0.00	0.01	
70-79	166	16 744	0.01	0.01	0.01	123	21 042	0.01	0.00	0.01	
80-89	272	30 594	0.01	0.01	0.01	169	38 359	0.00	0.00	0.01	
\geq 90	162	24 256	0.01	0.01	0.01	95	30 300	0.00	0.00	0.00	
Crude ^{*a}	758	70 765	0.01	0.01	0.01	563	88 701	0.01	0.01	0.01	
SMR			0.01	0.01	0.01			0.01	0.01	0.01	

Table S4| Rate ratio for all-cause death by age by dose of vaccination.

*a: Total all-cause deaths did not equal totals for each age group because they include persons of unknown age.

Abbreviations

Observed: Ob, Expected: Ex, Lower limit of 95% confidence interval: LL, Upper limit of 95% confidence interval: UL, Standardized mortality ratio: SMR.

	Overall							
Age (years)	Ob	Ex	Rate ratio	LL	UL			
12-19	7	133	0.05	0.02	0.11			
20-29	31	470	0.07	0.04	0.09			
30-39	34	833	0.04	0.03	0.06			
40-49	54	2 518	0.02	0.02	0.03			
50-59	93	6 151	0.01	0.01	0.02			
60-69	126	14 604	0.01	0.01	0.01			
70-79	302	37 786	0.01	0.01	0.01			
80-89	458	68 953	0.01	0.01	0.01			
\geq 90	267	54 555	0.00	0.00	0.01			
Crude ^{*a}	1 374	159 466	0.01	0.01	0.01			
SMR			0.01	0.01	0.01			

Table S4(continued)| Rate ratio for all-cause death by age by dose of vaccination.

*a: Total all-cause deaths did not equal totals for each age group because they include persons of unknown age.

Abbreviations

Observed: Ob, Expected: Ex, Lower limit of 95% confidence interval: LL, Upper limit of 95% confidence

interval: UL,

Standardized mortality ratio: SMR.

Table 55 Northing ouds faile for myocardins death by age.								
Age (years)	Mortality odds ratio (MOR)	LL	UL					
12-19	0.06	0.00	210.82					
20-29	67.51	12.12	246.65					
30-39	240.16	80.28	632.36					
40-49	82.07	15.83	267.82					
50-59	28.25	0.69	168.08					
60-69	103.03	20.58	317.58					
70-79	164.45	58.49	374.68					
80-89	277.05	107.47	600.76					
\geq 90	367.11	41.74	1 497.67					
Crude	209.82	146.06	301.41					
Pooled *a	148.49	89.18	247.25					

Table S5| Mortality odds ratio for myocarditis death by age

*a: Pooled mortality odds ratios were expressed based on random effect model.

Abbreviations

Observed: Ob, Expected: Ex, Lower limit of 95% confidence interval: LL,

Upper limit of 95% confidence interval: UL,

Standardized mortality ratio: SMR.

Table S6 | Causal inference of increased risk of myocarditis mortality and SARS-CoV-2 vaccine use by applying modified US Surgeon General's criteria of causality referencing Hill's viewpoints.

#	US Surgeon General's Criteria	No of Hill's viewpoint	Comment	Status
1	Temporality of association	#4	Very strong association; all events occurred after the vaccination. Moreover, onset of many death cases occurred within a short period after dose 1 or dose 2 of vaccine administration. Myocarditis symptoms leading to death occurred within 1 week in 50 % and within 2 weeks in 72 % of myocarditis death cases.	Y
2	Consistency of association	#2	Similar risk levels on the incidence of myocarditis and/or pericarditis were reported from various countries ¹⁴⁻¹⁸ , although they did not take healthy-vaccinee effect into account.	Y
3	Strength of association	#1	1) Strong association with high myocarditis mortality rate ratio (MMRR): Even without consideration of healthy-vaccinee effect, association measures for the risk of myocarditis death in the age of 30s were very strong (MMRR= 7.80). If healthy-vaccinee effect were taken into account, MMRR may be more than 7.0 for overall age which shows very strong association. Approximate 150 of pooled mortality odds ratio (MOR) also showed strong association.	Y
		#5	 2) Biological gradient (dose-response): Most of the epidemiological studies showed that the incidence rate of myocarditis or myopericarditis after the 2nd dose was higher than that after 1st dose. For example, according to the data by Mevorah et al¹⁴ rate ratio of 2nd dose of BNT122b2 to 1st dose was 3.76 (95%CI: 2.40 to 5.90) for all and 8.40 (2.08 to 33.83) for male aged 16 to 19; By the other all 3 studies,¹⁶⁻¹⁸ rate ratios of 2nd dose of mRNA-1273 to 1st dose were 5.06 or higher (lower limit of 95%CI were all 1.6 or higher). Our study showed that ratio of SMR after 2nd dose to that after 1st dose (1.36; 0.69 to 2.68) was not significant but is rather consistent with the tendency of the gradient for the incidence rate ratios of myocarditis from other studies. 	
Y=0	criterion satisfied	#3 I. X= criterion	3) Specificity: Myocarditis death is not a specific adverse reaction to SARS-CoV-2 vaccine and myocarditis death is caused not only SARS-CoV-2 vaccine but also by other vaccines and viruses or as an autoimmune disease. However, this is not an obstacle for satisfaction of this criterion "strength of association". not satisfied.	

Table S6 (continued) | Causal inference of increased risk of myocarditis mortality and SARS-CoV-2 vaccine use by applying modified US Surgeon General's criteria of causality referencingHill's viewpoints.

#	US Surgeon	No of Hill's	Comment	Status		
	General's	viewpoint				
	Criteria					
4	Coherence	#6	1) Biological plausibility: Some biological mechanisms were	Y		
	of		suggested such as increased interleukin-18 dependent immune			
	association		responses to explain the association of myocarditis and			
			vaccination. ⁵⁹			
		#7	2) Coherence: There is no conflicting findings that deny the			
			causality of myocarditis and SARS-CoV-2 vaccines.			
	#8 3) Experiment: Randomized controlled trials did not report					
			increased risk of myocarditis, but the population of the RCTs			
			were not large enough to detect the risk. Real world use of			
			vaccination may be considered as semi-experiment which was			
			included in this viewpoint (#8) by Hill. Many studies on the			
			semi-experiment reported the association almost without			
	exception.					
	#9 4) Analogy: Other vaccines (e.g., smallpox) have been report					
			to be associated with myocarditis or myopericarditis as one of			
			the adverse reactions. ⁶⁰ Three different products of SARS-CoV-			
			2 vaccine (ChAdOx1, BNT122b2 and mRNA-1273) showed			
			association of increased risk of myocarditis, although the			
			highest risk was reported for mRNA-1273.			

Y=criterion satisfied. X= criterion not satisfied.

59. Won T, Gilotra NA, Wood MK, et al. Increased Interleukin 18-Dependent Immune Responses Are Associated With Myopericarditis After COVID-19 mRNA Vaccination *Front Immunol* 2022; 13: 851620. doi: 10.3389/fimmu.2022.851620.

60. Decker MD, Garman PM, Hughes H, et al. Enhanced safety surveillance study of ACAM2000 smallpox vaccine among US military service members. *Vaccine* 2021; 39(39): 5541-47. doi: 10.1016/j.vaccine.2021.08.041.

Vaccine type	Case No	o Age	Sex	Last vaccinated date	Date of death	Number of vaccination	Comorbidities, histories leading to death	Cause of death diagnosed by physician	Corresponding MedDRA terms	Tests for the base of diagnosis	Causal assessment by physician	Causal assessment by experts
mRNA -1273 (Moderna)	44	24	Male	14 August 2021	17 August 2021	2nd	Details unknown. The first vaccination was given on 17 July 2021. He developed a fever up to 38 °C, the day after the second vaccination. Two days after vaccination, the fever broke, but he complained of a headache. Three days after the vaccination he did not attend work and was found dead at home.	Acute myocarditis	Myocarditis	Autopsy (lymphocyte- dominated inflammatory cell infiltrate around myocardial arterioles. Diagnosis of acute myocarditis as cause of death, as there was necrosis of the myocardium, scattered fibrosis, mild lymphocytic infiltration of pericoronary adipose tissue and no other evidence of fatal endogenous lesion damage.)	Could not be assessed	Could not be assessed

Available at: <u>https://www.mhlw.go.jp/content/10601000/000961526.pdf</u> [in Japanese] (Accessed 13 December 2022)

Fig S1. Examples of description in the Summary List of Deaths Following SARS-CoV-2 vaccination used by Japan's Ministry of Health, Labour and Welfare's Expert Committee on vaccination and adverse reactions.



Arrow lengths indicate time from onset to death.

Fig S2a. Method for counting deaths in the reference population.



Arrow lengths indicate time from onset to death.

Fig S2b. Method for counting deaths in the vaccinated population.